文章核心观点 - 一名股东代表投资者对Verve Therapeutics公司提起证券集体诉讼 [1] - 该诉讼指控Verve Therapeutics公司在2022年8月9日至2024年4月1日期间做出了虚假陈述 [1] 公司概况 - Verve Therapeutics是一家生物技术公司,专注于开发基因编辑疗法 [1] - 公司的主要产品是VERVE-101,正在进行心脏疾病的临床试验 [1] 诉讼指控 - 公司对VERVE-101心脏1期临床试验何时停止做出了虚假陈述 [1] 诉讼进展 - 如果投资者希望担任集体诉讼的代表原告,需要在2024年10月15日之前提交相关文件 [2] - 原告代表将代表其他集体成员指导诉讼,但不需要担任代表原告也可以获得赔偿 [2] - 该诉讼由Bernstein Liebhard LLP律师事务所负责,他们过去曾为客户赢得超过35亿美元的赔偿 [2]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Verve To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Verve between August 9, 2022 and April 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983- 9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 31, 2024 /PRNewswire/ -- ...

janiecbros/iStock via Getty Images Investment Overview - Recapping the Verve In Vivo Thesis It has been almost 10 months since Seeking Alpha published my last coverage of Verve Therapeutics, Inc. (NASDAQ:VERV). As a reminder, per the company's Q2 2024 quarterly report / 10Q submission, Verve is: a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic management to single-course gene editing medicines. We ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Verve To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Verve between August 9, 2022 and April 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983- 9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 29, 2024 (GLOBE NEWSWIRE ...

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve" or the "Company") (NASDAQ: VERV) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Verve securities between August 9, 2022, and April 1, 2024, both dates inclusive (the "Class Period"). Investors h ...

NEW YORK, Aug. 28, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 28, 2024 in the securities class action first filed by the Firm. So wha ...

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics, Inc. (NASDAQ: VERV) securities between August 9, 2022 and April 1, 2024. Verve is a "clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines." For more information, ...

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve Therapeutics" or "the Company") (NASDAQ: VERV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise a ...

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Verve Therapeutics, Inc. ("Verve" or the "Company") (NASDAQ: VERV) securities between August 9, 2022 and April 1, 2024, inclusive (the "Class Period"). The lawsuit seeks to recover damages for the Company's investors under the federal ...

ATLANTA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve Therapeutics" or "the Company") (NASDAQ: VERV). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and prospects, including allegations that: (1) Defendants did not fully disclose the circumstances under which the Heart-1 trial would be halted; and (2 ...